Peptide Sciences Shuts Down: What the Grey Market Collapse Means for You

Important: We are not doctors. This article is for educational purposes only. We are not recommending any vendor, product, or source for peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

---

Key Facts

• Peptide Sciences shut down on March 6, 2026. The company was one of the largest "research use only" peptide vendors in the United States, with estimated revenue of $7.4 million per month (Grips Intelligence, December 2025).
• At least 7 research peptide vendors have shut down or been forced offline since 2025.
• The FDA raided Amino Asylum's warehouse in June 2025 in coordination with the Department of Justice.
• U.S. peptide and hormone compound imports hit $328 million in Q1-Q3 2025, up from $164 million in the same period the previous year. The market doubled even as enforcement increased.
• The SAFE Drugs Act (H.R. 6509), introduced December 9, 2025, specifically closes the "research use only" loophole for compounds identical to FDA-approved drugs.
• Meanwhile, RFK Jr. announced that 14 of 19 banned peptides may return to legal compounding channels. But no formal FDA action has been published.

---

Timeline

Date	Event
September 2023	FDA places 19 peptides on Category 2 list, banning compounding
December 2024	FDA warning letters to Prime Peptides, Xcel Peptides, SwissChems, Summit Research
February 2025	FDA declares semaglutide shortage resolved
June 2025	Federal raid on Amino Asylum warehouse (FDA + DOJ)
September 2025	50+ FDA warning letters to GLP-1 compounders
December 9, 2025	SAFE Drugs Act (H.R. 6509) introduced in Congress
December 2025	FDA warning letter to Pinnacle Peptides for SARMs violations
February 27, 2026	RFK Jr. announces 14-peptide reclassification on Joe Rogan Experience
March 3, 2026	FDA sends 30 warning letters to GLP-1 telehealth firms
March 6, 2026	Peptide Sciences shuts down

---

What This Means

The grey market for research peptides is collapsing in real time. Peptide Sciences was the biggest name in the space, and its shutdown is not an isolated event. It is part of a pattern.

The Enforcement Wave

The FDA has been building this case for two years. The September 2023 Category 2 ban eliminated the legal basis for compounding 19 popular peptides, including BPC-157, TB-500, GHK-Cu, and Ipamorelin. That pushed demand onto vendors selling peptides labeled "for research use only."

The FDA's position has been consistent: the "research use only" label is a fiction when a product is clearly marketed for human consumption. If a website lists dosing instructions, reconstitution guides, and injection protocols alongside a "not for human use" disclaimer, the FDA treats that as an unapproved drug, not a research chemical.

The enforcement escalated through 2025. Warning letters came first. Then came the Amino Asylum raid, which signaled criminal prosecution was on the table. The SAFE Drugs Act, if passed, would close the research-use loophole entirely for any compound identical to an FDA-approved drug.

The Paradox: Demand Is Up, Supply Is Disappearing

Here is the strange part. U.S. peptide imports nearly doubled year-over-year ($164 million to $328 million, Q1-Q3 2025). Demand did not go away when the FDA tightened enforcement. It scattered.

That is the worst possible outcome for patient safety. Instead of buying from a handful of large, semi-established vendors like Peptide Sciences, buyers are now spread across dozens of smaller, less accountable suppliers. Quality control varies wildly. Testing transparency drops. Counterfeiting risk increases.

This is exactly the dynamic RFK Jr. pointed to when he said: "We created the black market."

What RFK Jr.'s Reclassification Means (and Does Not Mean)

On February 27, 2026, HHS Secretary Kennedy announced that roughly 14 of the 19 banned peptides would be moved back to Category 1, making them legal for compounding pharmacies to prepare with a valid prescription.

But as of March 14, 2026, no formal FDA rulemaking has been published. A podcast announcement does not have regulatory force. Until the FDA formally updates the Category 2 list, the legal status of these peptides has not technically changed.

If the reclassification does become official, it would redirect demand back toward licensed compounding pharmacies and away from the grey market. That would be a net positive for quality and safety. But the timeline is uncertain.

Three Things Happening at Once

1. Grey market vendors are shutting down (Peptide Sciences, 7+ others, Amino Asylum raided)
2. Legal compounding channels may reopen (RFK reclassification pending)
3. The SAFE Drugs Act could close the research-use loophole for GLP-1 compounds specifically

The market is in a transition state. Old channels are disappearing faster than new ones are opening.

---

What to Watch

• SAFE Drugs Act progress. If H.R. 6509 passes, vendors selling compounds identical to FDA-approved drugs (like semaglutide or tirzepatide) under "research use" labels will face explicit criminal liability.
• FDA formal rulemaking on Category 2 list. The RFK announcement needs to be followed by an actual Federal Register notice. Watch for a PCAC (Pharmacy Compounding Advisory Committee) meeting or a proposed rule.
• More vendor shutdowns. If Peptide Sciences could not survive the regulatory pressure, smaller vendors with fewer legal resources are at higher risk.
• Compounding pharmacy pricing. If peptides return to Category 1, expect compounding pharmacy prices ($150-$500+ per month) to compete with grey market prices ($50-$200 per month). Cost will still be a barrier for many patients.
• State-level variations. California has stricter compounding rules than federal minimums. Texas and Florida are more permissive. Where you live may determine what you can access.

---

FAQ

Why did Peptide Sciences shut down?

The company has not published a detailed statement. The shutdown follows two years of increasing FDA enforcement against research peptide vendors, including warning letters, raids, and the introduction of legislation to close the "research use only" loophole.

Can I still buy research peptides from other vendors?

Some vendors remain online. However, the regulatory environment has changed significantly. The FDA has made clear that selling peptides with dosing instructions under a "research use" label does not exempt a product from drug regulations. Buyers should understand the legal and safety risks.

Are peptides going to become legal again?

Potentially. RFK Jr. announced on February 27, 2026 that 14 of 19 restricted peptides may return to Category 1 (legal compounding). But this has not been formalized. If it is, you would need a prescription and a licensed compounding pharmacy. It would not mean over-the-counter access.

What about BPC-157 and TB-500 specifically?

Both are on the list of peptides expected to return to Category 1 under the RFK reclassification. But as of today, both remain on the Category 2 (restricted) list. Their legal status has not technically changed.

Is this related to the compounded GLP-1 crackdown?

They are connected. The FDA crackdown on compounded GLP-1s targets telehealth companies marketing compounded semaglutide and tirzepatide. The grey market collapse affects a broader set of peptides, including research compounds that were never FDA-approved for any indication. Same enforcement agency, different targets.

What should I do if I am currently using grey market peptides?

Talk to your doctor. If you are using peptides for a medical purpose, a physician can evaluate whether a compounded or FDA-approved alternative exists. Self-sourcing from unregulated vendors carries real risk: unknown purity, inconsistent dosing, and no quality guarantees.

---

Sources

1. FDA Crackdown on Compounded GLP-1s: What Changed in 2026 - Peptide Nerds, March 2026
2. RFK Jr. and the 2026 Peptide Reclassification - Peptide Nerds, March 2026
3. SAFE Drugs Act, H.R. 6509 - 119th Congress, December 2025
4. FDA Concerns with Unapproved GLP-1 Drugs - FDA.gov, Updated February 2026
5. Grips Intelligence peptide vendor revenue estimates, December 2025

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research, not medical recommendations.

Last updated: March 14, 2026